Novo Nordisk rebrands to Novo to boost obesity drug visibility

Novo Nordisk announced a brand name change to 'Novo' to increase market visibility for its obesity medications, with a logo update. The legal name remains unchanged. This is a cosmetic rebranding with no operational or financial impact, but it signals the company's strategic focus on the obesity market.